PEPTIDES
A GLP-1/Glucagon Peptide Cut Heavy Drinking Days in a Trial. It Is Not an Addiction Drug Yet
The most interesting metabolic-drug story may not be about the scale. It may be about what happens to the reward systems that influence behavior.
In...
PEPTIDES
A Self-Assembling Peptide Matrix Enters U.S. Wound Care. Evidence Still Matters
Peptide coverage has become so dominated by weight-loss injections that another part of the industry is easy to miss: materials made from peptides rather...
PEPTIDES
A Peptide Against Beta-Catenin Moves Toward a Precancer Trial. ST316 Faces a Difficult Target
The problem with some of cancer's most important signaling pathways is that healthy cells need them, too. A drug that shuts down the wrong...
PEPTIDES
After the Weight Comes Off, Can a Different Peptide Help Keep It Off?
Weight-loss trials have trained the public to expect one number: the percentage of body weight lost after a fixed period. It is a useful...
PEPTIDES
AbbVie’s Amylin Drug May Stretch Obesity Injections to a Month. The Evidence Is Still Early
The obesity-drug industry has spent years proving that people can lose substantial weight by manipulating gut and metabolic signaling. The next commercial challenge may...
PEPTIDES
Gilead Put $1.275 Billion Behind an Oral Macrocyclic Peptide. The Target Is Inflammation
A peptide that can be swallowed and still reach a therapeutically relevant target is an unusually valuable proposition.
Gilead's October 22 agreement to acquire PepStar...
PEPTIDES
A Bicyclic Peptide Gets Orphan Status in Pancreatic Cancer. The Trial Still Has to Deliver
Nuzefatide pevedotin is designed to target EphA2 and deliver a cytotoxic payload. Conceptual illustration, not an experimentally determined...
PEPTIDES
Enicepatide’s Diabetes Signal Shows Why Glucose Control Is Still a Separate Race
The obsession with pounds lost can obscure what diabetes medicines are designed to do first: control glucose. Genentech's investigational enicepatide, also known as CT-388,...
